Speed Is Everything In CGRP Race As Amgen/Novartis Reveal Phase III Data

 
• By Mandy Jackson

Amgen and Novartis revealed the first set of Phase III data for a CGRP inhibitor in the treatment of episodic migraine, potentially positioning the companies’ biologic erenumab at the head of the drug class.

More from Neurological

More from Therapy Areas